To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Study Type
OBSERVATIONAL
Enrollment
200
Dual anti-HER2 therapy
Progression free survival(PFS)
The time from starting pyrotinib until disease progression or death from any cause.
Time frame: 1 year
Overall survival(OS)
The time from starting pyrotinib until death, regardless of cause.
Time frame: 1 year
Objective Response Rate(ORR)
The proportion of patients with complete response (CR) or partial response (PR)
Time frame: 1 year
Safety
Number of participants with adverse events which were collected at 6 and 18 months after the start of pyrotinib
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.